Skip to main content
Fig. 1 | Cost Effectiveness and Resource Allocation

Fig. 1

From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain

Fig. 1

Structure of the Markov model. a Follow-up treatment states: duplicated for each follow-up treatment. Patients not responding in the first 6 months of follow-up treatment move to the next treatment in the sequence. b Reason for discontinuation (lack of efficacy or adverse events) determined by the probabilities after leaving treatment health state

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us